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We assessed the prevalence of chronic kidney disease (CKD)
in a hospital-based screening program in Okinawa, Japan.
The significance of metabolic syndrome as a determinant of
CKD was examined using multivariate logistic regression
analysis. A total of 6980 participants, aged 30–79 years,
participated in a screening program in Tomishiro Chuo
Hospital. Metabolic syndrome was defined according to the
criteria of the Adult Treatment Panel III (ATP III). Data were
also analyzed according to the modified criteria of the
National Cholesterol Education Program (NCEP) that defines
abdominal obesity as a waist circumference of X85 cm in
men and X90 cm in women. CKD was defined as dipstick
proteinuria (X1þ ) or a reduced glomerular filtration rate
(GFR). GFR was estimated using the abbreviated Modification
of Diet in Renal Disease (MDRD) formula. The prevalence of
metabolic syndrome and CKD was 12.8 and 13.7%,
respectively. Metabolic syndrome was a significant
determinant of CKD (adjusted odds ratio (OR) 1.537 and 95%
confidence interval (CI) 1.277–1.850, Po0.0001). The adjusted
OR (95% CI) was 1.770 (1.215–2.579, P¼ 0.0029) for those
with four metabolic syndrome risk factors compared to those
with no metabolic syndrome risk factors. Metabolic
syndrome was a significant determinant for younger
participants (o60 years; OR 1.686, 95% CI 1.348–2.107,
Po0.0001), but not for older participants (X60 years; OR
1.254, 95% CI 0.906–1.735, NS). The relationship between the
number of metabolic syndrome risk factors and the
prevalence of CKD was linear using the modified criteria.
The results suggest that metabolic syndrome is a significant
determinant of CKD in men under 60 years of age, in
Okinawa, Japan.
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The number of patients with end-stage renal disease (ESRD)
requiring chronic dialysis therapy is increasing worldwide.1–3
In Japan, Okinawa has the highest incidence of ESRD.1,4
Factors explaining such phenomena are likely targets
for intervention to reduce ESRD.5 In a community-based
population study, Fox et al.6 demonstrated that established
cardiovascular disease risk factors are associated with the
development of new-onset kidney disease. Metabolic syn-
drome is a common phenotype that increases the risk for
chronic kidney disease (CKD) among US adults.7,8 Obesity
relates to hyperlipidemia, hypertension, coronary artery
disease, and diabetes.9 We recently reported that obesity is
a significant predictor for developing ESRD, particularly in
men.10 Kubo et al.11 demonstrated that hyperinsulinemia
is a significant risk factor for renal dysfunction. Therefore,
metabolic syndrome is closely related to the prevalence of
CKD. The prevalence of obesity, however, is quite different
between Japan and the US. It is possible that the relationship
between body mass index and metabolic impairment differs
among ethnicities. The relation of metabolic syndrome to the
prevalence of CKD in the Japanese is not known.
We studied the prevalence of CKD, stratified by sex and
age, using a hospital-based registry. We also investigated the
relationship between the number of metabolic risk factors
and the prevalence of CKD.
RESULTS
We studied 6980 (3834 men, 3146 women) participants. The
mean (standard deviation (s.d.)) age was 49.6 (9.7) years,
with a range of 30–79 years (Table 1). Among all participants,
45.2% had elevated blood pressure, 14.3% had high plasma
glucose levels, 26.9% had high triglyceride levels, 17.4% had
low high-density lipoprotein (HDL) cholesterol levels, and
12.0% had abdominal obesity. We identified 865 (517 men,
348 women) participants who met the Adult Treatment Panel
III (ATP III) criteria (Table 2). The prevalence of metabolic
syndrome stratified by age and sex is shown in Figure 1.
Overall, 12.4% of the study participants had metabolic
syndrome.
The prevalence of CKD increased with age in both men
and women, particularly those 60 years of age and over
(Figure 2). The prevalence of CKD increased with the
number of metabolic syndrome risk factors; the prevalence of
CKD was 11.0% in those with no metabolic risk factors,
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12.5% with one, 15.4% with two, 20.7% with three, 24.2%
with four, and 20.0% with five. The adjusted odds ratio
(OR) (95% confidence interval (CI)) was 0.879 (0.729–1.060,
not significant (NS)), 1.040 (0.849–1.272, NS), 1.416 (1.114–
1.801, P¼ 0.0045), 1.770 (1.215–2.579, P¼ 0.0029), and
1.113 (0.404–3.067, NS) when the number of metabolic syn-
drome risk factors increased from 1 to 5 (reference was zero
metabolic syndrome risk factors). When we used the
modified National Cholesterol Education Program (NCEP)
criteria, the adjusted ORs were 1.029 (0.839–1.263, NS), 1.062
(0.855–1.321, NS), 1.206 (0.950–1.531, NS), 1.744 (1.296–2.347,
P¼ 0.0002), and 2.109 (1.219–3.651, P¼ 0.0077), respectively
(Figure 3). There was a graded linear relationship between the
two factors using the modified NCEP criteria. There were very
few participants with five metabolic syndrome risk factors in
our cohort (n¼ 25, 0.36% of the total using the NCEP criteria;
n¼ 74, 1.06% of the total using the modified NCEP criteria).
Among the metabolic syndrome risk factors, the prevalence of
CKD was highest in the participants with a high fasting plasma
glucose (Figure 4). Table 3 shows the univariate and multi-
variate adjusted ORs of CKD. In the multivariate methods, the
presence of metabolic syndrome was a significant determinant
of CKD, particularly in the younger participants (o60 years
of age).
The relationship between fasting plasma glucose and
prevalence of CKD is summarized in Table 4. Among the
Table 1 | Clinical characteristics of the study subjects
Number of participants 6980
Men (%) 3834 (54.9%)
Age (years) 49.6 (9.7), 30–79
Body height (cm) 160.7 (8.7)
Body weight (kg) 62.7 (11.8)
Body mass index (kg/m2) 24.2 (3.4)
Systolic blood pressure (mmHg) 127.0 (17.2)
Diastolic blood pressure (mmHg) 79.4 (11.1)
Total protein (g/dl) 7.3 (0.4)
Serum albumin (g/dl) 4.5 (0.2)
Triglyceride (mg/dl) 129.8 (107.9)
HDL-cholesterol (mg/dl) 56.2 (14.2)
Serum urea nitrogen (mg/dl) 13.9 (3.6)
Fasting plasma glucose (mg/dl) 101.2 (20.8)
Fasting plasma insulin (mmol/l) 9.76 (6.07)
Serum creatinine (mg/dl) 0.8 (0.2)
Proteinuria (%) 4.0%
Proteinuria denotes 1+ or greater by dipstick.
Table 2 | Clinical characteristics between those with and
without metabolic syndrome (MS) among the study subjects
Without MS With MS P-value
Number of subjects 6115 865
Men (%) 3317 (54.2) 517 (59.8) 0.0023
Age (years) 49.1 (9.6) 52.8 (9.7) o0.0001
Body height (cm) 160.7 (8.6) 160.5 (9.1) NS
Body weight (kg) 61.5 (11.1) 70.9 (12.9) o0.0001
Body mass index (kg/m2) 23.7 (3.1) 27.4 (3.7) o0.0001
Waist circumference (cm) 82.8 (8.4) 92.5 (8.9) o0.0001
Systolic blood pressure (mmHg) 125.2 (16.5) 140.1 (15.5) o0.0001
Diastolic blood pressure (mmHg) 78.3 (10.8) 87.0 (9.8) o0.0001
Total protein (g/dl) 7.3 (0.4) 7.4 (0.4) o0.0001
Serum albumin (g/dl) 4.5 (0.2) 4.5 (0.2) NS
Triglyceride (mg/dl) 115.0 (79.8) 234.3 (190.9) o0.0001
HDL-cholesterol (mg/dl) 58.0 (13.9) 43.7 (9.3) o0.0001
Serum urea nitrogen (mg/dl) 13.8 (3.5) 14.0 (3.6) NS
Fasting plasma glucose (mg/dl) 101.2 (20.8) 118.9 (34.9) o0.0001
Fasting plasma insulin (mmol/l) 8.93 (5.2) 15.6 (8.2) o0.0001
HOMA index 2.2 (1.4) 4.6 (2.8) o0.0001
Serum creatinine (mg/dl) 0.8 (0.2) 0.8 (0.2) NS
GFR (ml/min/1.73 m2) 71.8 (10.2) 71.4 (12.5) NS
Proteinuria (%) 3.0% 11.2% o0.0001
CDK (%) 772 (12.6%) 185 (21.4%) o0.0001
Proteinuria denotes 1+ or greater by dipstick. NS=not significant. Chronic kidney
disease (CKD) was defined as an estimated GFR of less than 60 ml/min/1.73 m2 or
dipstick proteinuria (X1+). GFR was estimated using the abbreviated MDRD
formula.
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Figure 1 | Prevalence of metabolic syndrome in Okinawa, Japan,
by age and gender. Screening was performed between May 2003
and March 2004 at the Tomishiro Chuo Hospital. Metabolic syndrome
was defined using the criteria recommended in the NCEP ATP III
guidelines and modified NCEP criteria. Modified denotes NCEP ATP III
guidelines criteria that define abdominal obesity as a waist
circumference of 85 cm or more in men and 90 cm or more in
women.
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Figure 2 | Prevalence of CKD in Okinawa, Japan, by age and
gender. Screening was performed between May 2003 and March
2004 at the Tomishiro Chuo Hospital. CKD was defined as an
estimated GFR ofo60 ml/min/1.73 m2 or dipstick proteinuria (X1þ ).
GFR was estimated using the abbreviated MDRD formula. The
hatched horizontal line represents the mean CKD prevalence for the
entire population.
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participants with fasting plasma glucose 110–125 mg/dl,
5% were treated with hypoglycemic drugs. The preva-
lence of CKD increased as the mean fasting plasma glucose
increased. Effects of the presence or absence of metabolic
syndrome risk factors (high triglyceride levels and abdominal
obesity) on the prevalence of CKD are summarized in
Table 5. The impact of the presence of metabolic syndrome
risk factors (high triglyceride levels and abdominal obesity)
was larger in younger participants than in older participants.
The prevalence of each component of the metabolic
syndrome is summarized according to the number of
components (Table 6); high blood pressure and abdominal
obesity were considered to be the initial events of metabolic
syndrome.
DISCUSSION
Our study demonstrated a strong, positive relationship
between metabolic syndrome and the prevalence of CKD.
The identification of metabolic syndrome is important in
patients with a high risk of developing ESRD. The relation-
ship between the number of metabolic syndrome risk factors
and the prevalence of CKD was different from that reported
previously7 (Figure 3). The relationship between obesity and
metabolic impairment might differ according to ethni-
city.12,13 The relationship was similar, however, when we
used the modified NCEP criteria. The significance of insulin
resistance11 and metabolic syndrome7 was recently raised as a
factor in renal dysfunction. Also, the established cardio-
vascular disease risk factors are associated with the develop-
ment of new-onset kidney disease.6 In our cohort, the initial
event in the development of metabolic syndrome seemed
to be related to high blood pressure and abdominal obesity
(Table 6). Triglyceride-rich apolipoprotein B-containing
lipoproteins clearly promote the progression of human
renal insufficiency.14 High triglyceride levels are a risk factor
for developing proteinuria.15 Early detection of metabolic
syndrome or high triglyceride levels might be beneficial if
accompanied by early intervention such as statins to lower
triglyceride levels and suppress the pathways for renal injury.
The prevalence of CKD increased sharply in participants
after 60 years of age, while that of metabolic syndrome
increased gradually. Renal functions deteriorate in the aged
population for various reasons. These participants might
have had a renal disease, such as nephrosclerosis or ischemic
kidney disease. Causes of CKD were not examined further
in this cohort. Half of the participants were not aware of
their renal diseases. Hypertension was present, however, in
32.2%, proteinuria in 29.3%, and diabetes mellitus in 8.7%.
Glomerular filtration rate (GFR) of the CKD participants
(n¼ 957) was distributed as stages 1 and 2 in 213 participants
(22.3%), stage 3 in 735 (76.8%), and stage 4 in nine (0.9%). We
do not have information regarding the duration of metabolic
syndrome. The impact of high triglyceride levels or abdominal
obesity seemed to be larger in younger participants (Table 5).
The duration of metabolic syndrome might be longer in the
older participants (X60 years) than in the younger participants
(o60 years), and this might, at least partly, explain the higher
prevalence of CKD in the older participants.
There are several mechanisms underlying the effects of
metabolic syndrome on renal function and proteinuria.
Obesity is related to hyperlipidemia, hypertension,9,16
coronary artery disease, and diabetes. Obesity-related glo-
merulopathy is an increasingly prevalent condition.17 As the
GFR falls, protein and energy intake might decline in
moderate and advanced CKD.18 In the entire cohort,
however, renal function was normal (i.e., GFR X60 ml/
min/1.73 m2) in most of the participants (89.3%).
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Figure 3 | OR (95% CI) of CKD with the number of metabolic
syndrome risk factors. OR was adjusted for age and sex. CKD was
defined as an estimated GFR of less than 60 ml/min/1.73 m2 or
dipstick proteinuria (X1þ ). GFR was estimated using the abbre-
viated MDRD formula. Modified denotes NCEP ATP III guidelines
criteria that defines abdominal obesity as a waist circumference of
85 cm or more in men and 90 cm or more in women. *Po0.01.
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Figure 4 | Prevalence of CKD and each risk factor of the metabolic
syndrome. Metabolic syndrome was defined using the criteria
recommended in the NCEP ATP III guidelines. Modified denotes NCEP
ATP III guidelines criteria that defines abdominal obesity as a waist
circumference of 85 cm or more in men and 90 cm or more in
women. CKD was defined as an estimated GFR of o60 ml/min/
1.73 m2 or dipstick proteinuria (X1þ ). GFR was estimated using the
abbreviated MDRD formula. The hatched horizontal line represents
the mean CKD prevalence for the entire population.
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There are ethnic differences in diabetes mellitus-induced
organ damage and in the number of affected nephrons.
Asians tend to have more renal damage than Caucasians.19 In
Japan, diabetes mellitus has become the leading cause of new-
onset dialysis since 1998: 41% in 2003.1 There was a graded
linear relationship between fasting plasma glucose and the
prevalence of CKD (Table 4). The results support the notion
that hyperinsulinemia has a significant role in renal dys-
function,11 and therefore it is important to recognize the risk
of end-organ complications.20
The prevalence of metabolic syndrome in the present study
was about half (12.4%) that reported in the US (24.7%).7
When we used the modified NCEP criteria, however, the
Table 3 | Results of the logistic regression analysis on the determinants of CKD
Univariate Multivariate
Variables OR (95% CI) P-value OR (95% CI) P-value
All age group
Age (year) 1.067 (1.059–1.074) o0.0001 1.065 (1.057–1.073) o0.0001
Sex, vs women 1.122 (0.977–1.287) NS 1.172 (1.017–1.351) 0.0279
MS, vs no MS 1.883 (1.574–2.252) o0.0001 1.537 (1.277–1.850) o0.0001
Age X60 years
Age (year) 1.037 (1.007–1.069) 0.0152 1.037 (1.006–1.068) 0.0176
Sex, vs women 1.122 (0.865–1.454) NS 1.124 (0.866–1.459) NS
MS, vs No MS 1.267 (0.917–1.751) NS 1.254 (0.906–1.735) NS
Age o60 years
Age (year) 1.072 (1.059–1.086) o0.0001 1.070 (1.056–1.083) o0.0001
Sex, vs women 1.136 (0.962–1.342) NS 1.193 (1.007–1.413) 0.0410
MS, vs no MS 1.973 (1.585–2.456) o0.0001 1.686 (1.348–2.107) o0.0001
Metabolic syndrome (MS) was defined based on the criteria of the ATP III guidelines. Chronic kidney disease (CKD) was defined as a GFR less than 60 ml/min/1.73 m2 or
dipstick proteinuria (X1+). GFR was estimated using the abbreviated MDRD formula. NS=not significant.
Table 4 | Relation between fasting plasma glucose and the
prevalence of CKD
Fasting plasma glucose (mg/dl) o110 110–125 X126
Number of participants 5981 616 383
Mean (s.d.) 95.6 (6.9) 115.2 (4.3) 165.8 (46.2)
Fasting plasma insulin (mmol/l) 9.2 (5.5) 13.1 (7.1) 13.8 (8.7)
HOMA index 2.2 (1.4) 3.7 (2.0) 5.5 (3.6)
Proteinuria 175 (2.9%) 50 (8.1%) 55 (14.4%)
CKD (%) 772 (12.9%) 102 (16.6%) 83 (21.7%)
Chronic kidney disease (CKD) was defined as an estimated GFR ofo60 ml/min/
1.73 m2 or dipstick proteinuria (X1+). GFR was estimated using the abbreviated
MDRD formula.
Table 5 | Relation between the prevalence of CKD and
metabolic syndrome risk factor, high triglyceride levels, and
abdominal obesity, by age group
Prevalence of CKD
High triglyceride levelsa No Yes
Young (o60 years) 420/4246 (9.9%) 218/1579 (13.8%)
Elderly (X60 years) 228/858 (26.6%) 91/297 (30.6%)
Abdominal obesityb No Yes
NCEP criteria
Young (o60 years) 550/5200 (10.6%) 88/625 (14.1%)
Elderly (X60 years) 260/943 (27.6%) 59/212 (27.8%)
Modified NCEP criteria
Young (o60 years) 355/3651 (9.7%) 152/591 (25.7%)
Elderly (X60 years) 283/2174 (13.0%) 167/564 (29.6%)
aHigh triglyceride, 150 mg/dl and over.
babdominal obesity denotes abdominal circumference 102 cm and over in men or
88 cm and over in women (NCEP criteria) and abdominal circumference 85 cm and
over in men and 90 cm and over in women (modified NCEP criteria).
Table 6 | Prevalence of the components of metabolic
syndrome in each component
Metabolic syndrome
Risk factor
number NCEP criteria Modified NCEP criteria
n=1 BP 56.2% BP 46.8%
TG 17.6% OB* 23.8%
HDL 11.9% HDL 12.4%
OB 7.5% TG 11.5%
FPG 6.8% FPG 5.4%
n=2 BP, TG 33.3% OB*, BP 40.7%
BP, FPG 17.7% OB*, TG 13.7%
BP, OB 15.1% TG, BP 12.2%
TG, HDL 12.8% TG, HDL 7.1%
Others 21.1% Others 26.3%
n=3 BP, TG, FPG 27.7% OB*, BP, TG 35.5%
BP, TG, HDL 26.9% OB*, BP, FPG 19.8%
BP, HDL, OB 9.6% OB*, TG, HDL 11.7%
BP, TG, OB 8.2% BP, TG, HDL 9.8%
Others 27.6% Others 23.2%
n=4 BP, TG, HDL, FPG 36.8% OB*, BP, TG, FPG 40.8%
BP, TG, HDL, OB 35.2% OB*, BP, TG, HDL 35.3%
BP, TG, FPG, OB 13.7% OB*, TG, HDL, FPG 10.4%
BP, HDL, FPG, OB 10.4% OB*, BP, HDL, FPG 9.0%
TG, HDL, FPG, OB 3.8% BP, TG, HDL, FPG 4.5%
BP=systolic blood pressure 130 mmHg and over or diastolic blood pressure
85 mmHg and over; OB=abdominal circumference 102 cm and over in men or
88 cm and over in women (NCEP); OB*=abdominal circumference 85 cm and over in
men and 90 cm and over in women (modified NCEP); TG=total glycerides 150 mg/dl
and over; FPG=fasting plasma glucose 110 mg/dl and over; HDL=high-density
lipoprotein cholesterol o40 mg/dl in men or o50 mg/dl in women.
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prevalence of metabolic syndrome increased to 21.2%. This
discrepancy might be related to the difference in the prevalence
and degree of obesity between the two countries.10,21,22
Metabolic syndrome was more prevalent in men and elderly
people. In younger women (o50 years), the prevalence of
metabolic syndrome was lower than that in men; whether this
is related to the hormonal environment is not known.
The potential limitations of our study should be noted.
First, the cohort was voluntary, and therefore it is biased by
the healthy worker effect. Those who were already under
treatment for cardiovascular disease or CKD might not
have participated. For reference, we compared our cohort
with the larger screening cohort in the Okinawa General
Health Maintenance Association registry.10 In the 2003
Okinawa General Health Maintenance Association registry
(n¼ 154 019), the mean levels of body mass index, fasting
plasma glucose levels, and proteinuria were 24.1 kg/m2,
102.4 mg/dl, and 4.3%, respectively (unpublished obser-
vations). Waist circumference is not measured in the
Okinawa General Health Maintenance Association. To our
knowledge, the present study is the first study concerning
CKD and metabolic syndrome in Okinawa and Japan.
Second, the cross-sectional study design makes it difficult
to infer causality between metabolic syndrome and risk for
CKD or proteinuria. We recently observed, however, that
obesity is a significant predictor of developing proteinuria23
and ESRD.10 Weight reduction is associated with a decrease
in proteinuria.24,25 Third, serum creatinine levels and calcu-
lated GFR have been used to define CKD.26 Although inulin
or iothalamate clearance techniques might provide a more
sensitive estimate of renal function, serum creatinine is
widely used in large epidemiologic studies and in clinical
practice for estimating renal function. Therefore, our findings
are applicable to clinical and public health practice settings.
Ethnic factors for the Japanese are not well established when
using the abbreviated Modification of Diet in Renal Disease
(MDRD) equation.27,28 Several studies demonstrate that the
Japanese have a lower GFR, which is not necessarily due to
renal disease, than white and black populations.29–31 There-
fore, our results might have underestimated the prevalence of
CKD. In contrast to our cohort, the prevalence of CKD is
uncommon in those who have no metabolic syndrome
components in the National Health and Nutrition Examina-
tion Survey III.7 Fourth, other parameters associated with
obesity and glucose metabolism, such as physical activity32
and alcohol consumption,33 were not examined in the
present study. Finally, while screening for early identification
of metabolic syndrome might improve health and prevent the
progression of renal disease, it could also lead to unnecessary
harm and excessive expenses. Whether the measurement of
abdominal circumference in addition to body weight and
height is superior to current screening practices in Japan5
remains to be examined.
In conclusion, metabolic syndrome is a strong and
independent risk factor of CKD, particularly in younger
men (o60 years of age). Early identification of metabolic
syndrome might be beneficial in preventing CKD and ESRD
in men of this age group.20 Actually, the incidence of diabetes
mellitus dialysis patients is increasing linearly only in men in
Japan.34 Thus, it might be as important to treat and prevent
obesity as it is to treat and prevent hypertension and
abnormal glucose metabolism for the prevention of CKD.
MATERIALS AND METHODS
Study participants
The participants of a 1-day health check in Tomishiro Chuo
Hospital who elected to undergo metabolic screening were studied.
All participants visited the hospital voluntarily and paid for the tests.
The hospital is the main private hospital, covering the city with a
population of approximately 50 000. Participants who visited
between May 2003 and March 2004 were studied. Those with
kidney failure (estimated creatinine clearance o15 ml/min, n¼ 4)
were excluded from the current analysis. In addition, those missing
data for proteinuria (n¼ 34) and serum albumin (n¼ 3) were
excluded. The study protocol was approved by the research and
ethics committee of the Tomishiro Chuo Hospital.
Data for this study were collected during a standard health check
in Tomishiro Chuo Hospital Registry at the Center for the Diabetes
and Lifestyle-Related Disorders. Information on sex, birth date, and
other pertinent medical data were obtained. Trained nurses, using a
standard protocol, measured blood pressure. Waist circumstance
was measured according to a standard protocol. A blood sample was
collected after an overnight fast of at least 8 hours. Plasma glucose
level was measured using a hexokinase enzyme reference method.
Serum HDL cholesterol and triglyceride levels were measured
enzymatically using a commercially available reagent mixture, and
creatinine was analyzed by the enzyme method (normal:
0.61–1.04 mg/dl for men, 0.47–0.79 mg/dl for women, using a
Hitachi 7170 automated analyzer, Tokyo, Japan). Serum creatinine
was calibrated using the following formula: serum creatinine (Yaffe
method)¼ 0.194þ 1.079 serum creatinine (enzyme method).
Metabolic syndrome was defined using the criteria recommended
in the NCEP ATP III guidelines.35 Specifically, elevated blood
pressure was defined as systolic or diastolic blood pressure of 130/
85 mmHg or higher; low HDL cholesterol level was defined as less
than 1.036 mmol/l (40 mg/dl) in men or less than 1.295 mmol/l
(50 mg/dl) in women; high serum triglyceride levels were defined as
1.695 mmol/l (150 mg/dl) or more; and elevated fasting plasma
glucose level was defined as 6.10 mmol/l (110 mg/dl) or more.
Finally, abdominal obesity was defined as a waist circumference of
102 cm or more in men or 88 cm or more in women. Metabolic
syndrome was defined as the presence of three or more of these
components. Data were also analyzed according to the modified
NCEP criteria defining abdominal obesity as a waist circumference of
85 cm or more in men and 90 cm or more in women. Diabetes was
defined as a self-reported history of a previous diagnosis of diabetes
or a fasting plasma glucose level of 7.0 mmol/l (126 mg/dl) or more.
Hypertension was defined as systolic blood pressureX140 mmHg or
diastolic blood pressure X90 mmHg. Estimated GFR was calculated
using the abbreviated MDRD formula.27 CKD was defined as a
GFR of o60 ml/min/1.73 m2 or dipstick proteinuria (X1þ ).26
Proteinuria was defined by a dipstick urinalysis score of 1þ or more.
Statistical analysis
The prevalence of metabolic syndrome and its individual compo-
nents (elevated blood pressure level, high plasma glucose level, high
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triglyceride level, low HDL cholesterol level, and abdominal obesity)
as well as the number of metabolic syndrome components present
(0, 1, 2, 3, 4, or 5) was determined for the overall study sample.
Mean values of continuous variables and percentages of categorical
variables for exposures, covariates, and outcomes were calculated
and grouped by metabolic syndrome status. The statistical signifi-
cance of differences in these characteristics across participants with
and without metabolic syndrome was examined using the Z test
(continuous variables) and the Wald w2 test (categorical variables) in
multivariate regression models after adjustments for age and sex. ORs
(95% CI) of CKD by the number of metabolic syndrome risk factors
were obtained using SAS (Version 8.2, SAS Institute Inc., Cary, NC,
USA). A P-value of less than 0.05 was considered statistically
significant.
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